drugset / Trial / NCT06531395
A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
Phase 2
Terminated
3 enrolled
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals, Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Primary objective of the study is to evaluate the effect of abiprubart on an established systemic disease activity measure for Sjögren's Disease.
Timeline
- Start
- 2024-07-17
- Primary completion
- 2025-03-06
- Completion
- 2025-05-01
Outcome
Outcome not reported
Stopped (Business): “Terminated due to strategic business decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiprubart | Monoclonal antibody | 400 mg | Subcutaneous |